Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Lipid Metabolism Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PAFAH1B3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PAFAH1B3 Recombinant Protein (Wild-Type) High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for enzyme activity and SPR binding assays. |
View PAFAH1B3 Products |
| Mutant Control | PAFAH1B3 (S47A) Mutant Recombinant Protein Active site serine-to-alanine mutation. Crucial negative control for validating covalent inhibitor mechanism of action. |
View PAFAH1B3 Products |
| Gene Delivery | PAFAH1B3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to support cellular target engagement assays. |
View PAFAH1B3 Products |
| Validator | PAFAH1B3 siRNA Set For knock-down verification in phenotypic and functional assays. |
View PAFAH1B3 Products |
| Related Target A | PAFAH1B2 Highly homologous sister catalytic subunit. Essential counter-screening target to ensure drug selectivity. |
View PAFAH1B2 Products |
| Related Target B | MGLL (Monoacylglycerol Lipase) Key serine hydrolase in cancer lipid metabolism; used for off-target selectivity profiling. |
View MGLL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against highly homologous PAFAH1B2 | Matched pair of recombinant PAFAH1B3 and PAFAH1B2 proteins, strictly sequence verified and purity checked via SDS-PAGE. |
| Covalent mechanism validation | S47A inactive mutant protein available to confirm specific covalent binding to the active site serine. |
| Assay reproducibility and stability | Expression in eukaryotic systems (HEK293/Sf9) to preserve native folding and post-translational modifications. |
| Cell-based target engagement | High-titer Lentiviral particles ready for stable cell line construction in cancer models. |
Live PAFAH1B3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PAFAH1B3 therapeutics is intensifying, with major players shifting focus from academic target validation to target-directed drug discovery. As an intracellular serine hydrolase that regulates crucial ether lipid metabolism pathways in aggressive cancer cells, PAFAH1B3 has emerged as a high-value metabolic oncogene. While first-generation pan-PAF acetylhydrolase inhibitors showed broad activity, the next wave of R&D is targeting highly selective covalent and non-covalent small molecule inhibitors to bypass systemic off-target toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Covalent Small Molecule | Academic/Biotech Consortiums | Breast Cancer, Ovarian Cancer, Melanoma | Active site mutant proteins (S47A) to prove specific covalent target engagement. |
| Non-Covalent Inhibitors | Preclinical Stage Biotechs | Prostate Cancer, Colorectal Cancer | High-purity wild-type enzyme for high-throughput biochemical screening (HTS). |
| Combination Therapies | Translational Research Labs | Drug-Resistant Solid Tumors | Lentivirus and siRNA for stable knockdown/overexpression in cell-based synergy assays. |